Hot Products
Hot products from BioCrick which is a professional high-purity natural products manufacturer are well known to scientists around the world because of their high purity and stability. Each product is a chemical compound or substance produced by a living organism—that is, found in nature. In the broadest sense, natural products include any substance produced by life.Natural products remain the best sources of drugs and drug leads, and this remains true today despite the fact that many pharmaceutical companies have deemphasized natural products research in favor of HTP screening of combinatorial libraries during the past 2 decades. From 1940s to date, 131 (74.8%) out of 175 small molecule anticancer drugs are natural product-based/inspired, with 85 (48.6%) being either natural products or derived therefrom. From 1981 to date, 79 (80%) out of 99 small molecule anticancer drugs are natural product-based/inspired, with 53 (53%) being either natural products or derived therefrom. Among the 20 approved small molecule New Chemical Entities (NCEs) in 2010, a half of them are natural products.
Hot products from the professional high-purity natural products manufacturer
| Cat.No. | Product Name |
|---|---|
| BCC6239 | LM 22A4 |
| Potent tropomyosin-related kinase B (TrkB) agonist. Induces activation of Trk, Akt and ERK in mouse hippocampus and striatum and exhibits neurotrophic activity. Reverses deficits in motor task learning in mice following traumatic brain injury; restores respiratory function in a rat model of Rett syndrome. | |
| BCC6240 | PBP 10 |
| Selective formyl peptide receptor 2 (FPR2) antagonist; cell permeable. Selectively inhibits FPR2-mediated NADPH oxidase activity but has no effect on FPR1 signaling in neutrophils. Displays PIP2 binding activity in vitro and blocks cell motility. Also exhibits antiviral activity against influenza viruses via inhibition of viral-induced ERK activation. | |
| BCC6241 | MKT 077 |
| Occupies mortalin-2 (mot-2), a member of the Hsp70 family, at its p53 binding site and enables p53 translocation to the nucleus. Selectively cytotoxic; causes growth arrest of cancer cells in culture. Also inhibits telomerase activity and cross-links F-actin. | |
| BCC6242 | MK 1903 |
| Potent and selective hydroxycarboxylic acid receptor 2 (HCA2, GPR109A) full agonist; exhibits greater potency than niacin in a whole cell HTRF-cAMP assay (EC50 values are 12.9 and 51 nM respectively). Exhibits no binding at the GRP109B receptor. | |
| BCC6243 | GSK2578215A |
| Potent LRRK2 inhibitor (IC50 values are 8.9 and 10.1 nM for LRRK2[G2019S] mutant and wild-type LRRK2 respectively). Displays selectivity for LRRK2 over a panel of 460 other kinases. Blocks Ser910 and Ser935 phosphorylation in vitro and in peripheral tissues in vivo. Brain penetrant. | |
| BCC6244 | TC-I 2000 |
| TRPM8 channel blocker. Inhibits icilin-induced TRPM8 channel activation in rTRPM8-expressing CHO cells (IC50 = 53 nM). | |
| BCC6246 | SC 79 |
| Activator of Akt; binds to the pleckstrin homology domain of Akt. Enhances Akt phosphorylation by upstream protein kinases; also enables cytosolic activation of Akt. Shown to suppress excitotoxicity-induced neuronal death in vitro and in vivo. Exhibits brain penetrance. | |
| BCC6248 | TT 232 |
| Peptide agonist for sst1/sst4 somatostatin receptors. Somatostatin analog; inhibits tyrosine kinase activity in human colon tumor cell lines. Demonstrates an antiproliferative effect both in vitro and in vivo and induces apoptosis in a pancreatic tumor cell line. Does not inhibit growth hormone release or secretion. | |
